Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Boundless Bio, Inc. Common Stock

Healthcare US BOLD

1.44USD
0.01(0.70%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.431.45
LowHigh

52 Week Range

0.961.78
LowHigh

Fundamentals

  • Previous Close 1.43
  • Market Cap35.85M
  • Volume134365
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-62.30100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -58.19700M -65.36300M -49.43400M -45.90100M -25.21000M
Minority interest - - - - -
Net income -58.19700M -65.36300M -49.43400M -45.90100M -25.21000M
Selling general administrative 18.71M 18.00M 12.16M 9.31M 6.02M
Selling and marketing expenses - - - - -
Gross profit -1.25100M -1.08600M -0.95700M -0.94200M -0.68200M
Reconciled depreciation 1.25M 1.09M 0.96M 0.94M 0.68M
Ebit -63.55200M -65.36300M -54.79600M -46.46900M -25.30100M
Ebitda -62.30100M -64.27700M -53.83900M -45.52700M -24.61900M
Depreciation and amortization 1.25M 1.09M 0.96M 0.94M 0.68M
Non operating income net other - - - - -
Operating income -63.55200M -73.26700M -54.79600M -46.46900M -25.30100M
Other operating expenses 63.55M 73.27M 54.80M 46.47M 25.30M
Interest expense - - - - -
Tax provision - - - - -
Interest income 5.36M 7.89M 5.28M 0.67M 0.10M
Net interest income 5.36M 7.89M 5.28M 0.67M 0.10M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -65.36300M -5.28200M -0.66800M -0.09600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 62.30M 72.18M 54.80M 46.47M 25.30M
Cost of revenue 1.25M 1.09M 0.96M 0.94M 0.68M
Total other income expense net 5.36M 7.90M 0.08M -0.10000M -0.00500M
Discontinued operations - - - - -
Net income from continuing ops -58.19700M -65.36300M -49.43400M -45.90100M -25.21000M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 157.06M 206.41M 129.89M 76.83M 113.72M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.03M 2.28M 3.45M 1.32M 1.54M
Total liab 58.41M 55.77M 256.98M 158.53M 151.91M
Total stockholder equity 98.65M 150.64M -127.08200M -81.69600M -38.18900M
Deferred long term liab - - - - -
Other current liab 7.88M 6.86M 4.94M 0.09M 0.21M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Capital stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Retained earnings -259.66900M -201.47200M -136.10900M -86.67500M -40.77400M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 17.87M 26.59M 23.71M 10.95M 34.29M
Cash and equivalents - - - - -
Total current liabilities 12.54M 8.13M 9.36M 7.73M 3.87M
Current deferred revenue - - - 3.90M 2.21M
Net debt 31.17M 21.05M -21.51100M -5.76800M -33.91200M
Short term debt 3.17M - 2.19M 2.34M 0.38M
Short long term debt - - - - -
Short long term debt total 49.03M 47.63M 2.19M 5.18M 0.38M
Other stockholder equity 358.26M 351.99M 8.98M 5.38M 2.76M
Property plant equipment - - - - -
Total current assets 109.61M 154.39M 124.20M 68.04M 74.57M
Long term investments - - - 0.00000M 34.99M
Net tangible assets - - - - -
Short term investments 89.71M 125.53M 97.05M 55.77M 38.74M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.49M 1.27M 2.22M 1.40M 1.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.06M 0.12M 0.04M -0.39800M -0.17500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.57M 0.66M 0.56M 0.53M 1.07M
Deferred long term asset charges - - - - -
Non current assets total 47.45M 52.02M 5.69M 8.79M 39.15M
Capital lease obligations 49.03M 47.63M 2.19M 5.18M 0.38M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 38.35M -26.10100M -38.26000M 16.13M -59.28500M
Change to liabilities - - - - -
Total cashflows from investing activities 37.80M -26.10100M - - -
Net borrowings - - - - -
Total cash from financing activities 0.14M 89.82M 97.90M 0.13M 105.53M
Change to operating activities - - - - -
Net income -58.19700M -65.36300M -49.43400M -45.90100M -25.21000M
Change in cash -8.71900M 2.88M 12.78M -23.33800M 22.99M
Begin period cash flow 27.15M 24.27M 11.48M 34.82M 11.83M
End period cash flow 18.43M 27.15M 24.27M 11.48M 34.82M
Total cash from operating activities -46.66100M -60.84100M -46.85500M -39.59600M -23.24800M
Issuance of capital stock 0.00000M 93.00M 99.67M 0.00000M 105.32M
Depreciation 1.25M 1.09M 0.96M 0.94M 0.68M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.14M 0.11M - - -
Other cashflows from financing activities 0.14M -3.17700M 97.90M 16.13M -59.28500M
Change to netincome - - - - -
Capital expenditures 0.55M 2.54M 0.63M 1.07M 2.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.46M -1.67800M -0.79900M 0.87M -0.83700M
Stock based compensation 6.12M 7.52M 3.34M 2.29M 1.16M
Other non cash items 0.70M -2.40200M 2.38M 1.70M 0.42M
Free cash flow -47.20700M -63.37700M -47.48800M -40.66200M -25.28200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
BOLD
Boundless Bio, Inc. Common Stock		 0.01 0.70% 1.44 - - - 0.36
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Boundless Bio, Inc. Common Stock

10955 Alexandria Way, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Jonathan E. Lim M.D. Co-Founder & Independent Chairman 1972
Mr. Zachary Hornby CEO, President & Director 1979
Dr. Christian Hassig Ph.D. Chief Scientific Officer 1973
Dr. Klaus W. Wagner M.D., Ph.D. Chief Medical Officer 1973
Ms. Jamilu E. Rubin Chief Financial Officer 1965
Ms. Jessica Oien J.D. Chief Legal Officer & Corporate Secretary 1972
Mr. Neil Abdollahian M.B.A., M.S. Chief Business Officer 1973
Mr. Anthony Pinkerton Ph.D. Senior Vice President of Drug Discovery NA
Ms. Meredith Wesley Senior Vice President of Talent & Culture NA
Dr. Shailaja Kasibhatla Ph.D. Senior Vice President of Discovery & Translational Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.